Lucca Ilaria, de Martino Michela, Hofbauer Sebastian L, Zamani Nura, Shariat Shahrokh F, Klatte Tobias
Department of Urology, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Department of Urology, Centre hospitalier universitaire vaudois, Lausanne, Switzerland.
World J Urol. 2015 Dec;33(12):2045-52. doi: 10.1007/s00345-015-1559-7. Epub 2015 Apr 17.
Pretreatment measurements of systemic inflammatory response, including the Glasgow prognostic score (GPS), the neutrophil-to-lymphocyte ratio (NLR), the monocyte-to-lymphocyte ratio (MLR), the platelet-to-lymphocyte ratio (PLR) and the prognostic nutritional index (PNI) have been recognized as prognostic factors in clear cell renal cell carcinoma (CCRCC), but there is at present no study that compared these markers.
We evaluated the pretreatment GPS, NLR, MLR, PLR and PNI in 430 patients, who underwent surgery for clinically localized CCRCC (pT1-3N0M0). Associations with disease-free survival were assessed with Cox models. Discrimination was measured with the C-index, and a decision curve analysis was used to evaluate the clinical net benefit.
On multivariable analyses, all measures of systemic inflammatory response were significant prognostic factors. The increase in discrimination compared with the stage, size, grade and necrosis (SSIGN) score alone was 5.8 % for the GPS, 1.1-1.4 % for the NLR, 2.9-3.4 % for the MLR, 2.0-3.3 % for the PLR and 1.4-3.0 % for the PNI. On the simultaneous multivariable analysis of all candidate measures, the final multivariable model contained the SSIGN score (HR 1.40, P < 0.001), the GPS (HR 2.32, P < 0.001) and the MLR (HR 5.78, P = 0.003) as significant variables. Adding both the GPS and the MLR increased the discrimination of the SSIGN score by 6.2 % and improved the clinical net benefit.
In patients with clinically localized CCRCC, the GPS and the MLR appear to be the most relevant prognostic measures of systemic inflammatory response. They may be used as an adjunct for patient counseling, tailoring management and clinical trial design.
全身炎症反应的预处理测量指标,包括格拉斯哥预后评分(GPS)、中性粒细胞与淋巴细胞比值(NLR)、单核细胞与淋巴细胞比值(MLR)、血小板与淋巴细胞比值(PLR)以及预后营养指数(PNI),已被公认为透明细胞肾细胞癌(CCRCC)的预后因素,但目前尚无研究对这些标志物进行比较。
我们评估了430例接受临床局限性CCRCC(pT1 - 3N0M0)手术患者的预处理GPS、NLR、MLR、PLR和PNI。采用Cox模型评估与无病生存期的关联。用C指数测量辨别力,并使用决策曲线分析来评估临床净效益。
在多变量分析中,所有全身炎症反应指标均为显著的预后因素。与单独的分期、大小、分级和坏死(SSIGN)评分相比,GPS的辨别力提高了5.8%,NLR提高了1.1 - 1.4%,MLR提高了2.9 - 3.4%,PLR提高了2.0 - 3.3%,PNI提高了1.4 - 3.0%。在对所有候选指标进行的同时多变量分析中,最终的多变量模型包含SSIGN评分(HR 1.40,P < 0.001)、GPS(HR 2.32,P < 0.001)和MLR(HR 5.78,P = 0.003)作为显著变量。同时加入GPS和MLR可使SSIGN评分的辨别力提高6.2%,并改善临床净效益。
在临床局限性CCRCC患者中,GPS和MLR似乎是全身炎症反应最相关的预后指标。它们可作为患者咨询、制定治疗方案和临床试验设计的辅助手段。